Original Source(s)
Related Content
Does TYK2/JAK1 Show Potential in Inflammatory Diseases?
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.
July 6, 2026
-
3 min
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
AI Scribes Lag Clinicians on Note Quality
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
by Kerri Miller
April 17, 2026
-
6 min